Amplia Therapeutics Limited (ATX.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.079 (+1.28%) as of
Key statistics
- Market cap
- 40.55M
- Forward P/E
- -11.29
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0760 – 0.2750
- Beta
- -0.33
- Revenue (TTM)
- 4.79M
- Profit margin
- -160.86%
- Analyst target
- A$0.42
- Volume
- 315.98k
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.